semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Lung Cancer Persons 50-75 Asymptomatic for lung cancer Current or former (stopped smoking less than 10 years ago) cigarette smokers History of cigarette smoking of at least 20 pack years History of cigarette smoking with a family history of lung cancer which gives an individual a personal risk similar to a smoking history of 20 pk/years (i.e. 1% at 5 years) Mentally competent individuals to sign an informed consent Healthy enough to undergo pulmonary resection or stereotactic body radiotherapy A fully informed signed consent form must have been obtained
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL > 18 OLD THAT TAKE MORE THAN 1 WEEK  LIVER
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Patients of both sexes, aged 18 years or above, with a diagnosis of heart failure with systolic dysfunction (ejection fraction ≤ 45%), hospitalized for decompensation of HF Who agree to participate in the study by signing the Informed Consent  Patients with communication disabilities and people with degenerative neurological diseases Are also excluded patients who presented acute coronary syndrome (ACS) in the last 6 months before randomization Patients with renal, hepatic, pulmonary or systemic disease that may confuse the interpretation of the findings or result in limited life expectancy Surgical plan or therapeutic that might influence the follow-up Pregnancy, diagnosis of acute heart failure secondary to sepsis myocarditis myocardial infarction acute peripartum and other cause Have no interest in receiving home visits
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 20.0-55.0,  Abdominal Fat Body Weight Healthy subject, as determined by clinical examination, and medical history Non-menopausal woman BMI between 27 and 34 kg/m² Waist circumference > 80 cm No diet within the last 3 months with weight loss or gain not more than 3kg Non-smoking subject, or smoking less than 15 cigarettes/day since three months Normal blood pressure (BP) and heart rate (HR) after 10 minutes in supine position. Individuals values out of the normal range can be accepted if judged clinically non relevant by the investigator Laboratory parameters within the normal range of the laboratory (haematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator Subject with a habitual low (< 16 g/day) intake of whole grain foods (from cereal food intake questionnaire) willing to eat breakfast cereals  Subject having a history of metabolic disease (i.e, diabetes) Subject suffering from chronic renal insufficiency Subject receiving a local or general treatment (i.e, prescription medications, over-the-counter medications, dietary supplements or herbal supplements) susceptible to interfere with the evaluation of the studied parameters and in particular weight (eg, appetite suppressants, slimming or treatment which could interfere with the metabolism and dietary behaviour) Subject with ongoing medication not stabilized since more than 3 months Subject having had a general anaesthesia in the month preceding or gastro-intestinal surgery at any time in his/her life, with the possible exception of appendectomy Pregnant or breast-feeding subject (positive urinary pregnancy test) Subject in an period of a previous study or having participated in another clinical study in the last month Use of laxatives, except in few occasions, if, in the opinion of the investigator, does not interfere with the optimal participation Subject having received more than 4500 Euros in indemnity for participation in clinical studies in the last 12 months, including participation in the present study Subject in a situation that, in the opinion of the investigator, could interfere with his optimal participation in the study or constitute a particular risk for the subject
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chronic Abdominal Pain age 18-65 years abdominal pain at least 6 months previous abdominal surgery and/or significant abdominal trauma and/or abdominal infection ASA class I-II  psychiatric disorder significant other somatic diseases (ASA class III-V) refusal to participate
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Patients With Acute Pancreatitis Age>=18 years Diagnosis of acute pancreatitis confirmed by at least 2 of the following: 1. Typical epigastric abdominal pain 2. Elevation amylase/lipase >3 times upper limit normal and/or 3. Confirmatory findings on cross-sectional imaging Enrollment within 8 hours of presentation  Class II or greater NYHA heart failure Oxygen dependent COPD Chronic kidney disease>stage 2 Cirrhosis Existing necrosis on abdominal CT Organ dysfunction prior to enrollment Sepsis Acute respiratory distress syndrome Malignancy not in remission for at least 5 years Active drug use
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 20.0-34.0,  Type 2 Diabetes Mellitus You are one of a sibling pair with the same mother and father, and your mother had diabetes (gestational or type 2) while she was pregnant with the younger sibling but not the older sibling Your sibling is willing to participate in the study You are between the ages of 20 and 34 years (inclusive) Your body mass index is between 20 and 29 Kg/m2 inclusive (this is a number calculated for your height and weight and indicates that you are either normal weight or overweight, but not obese) You are healthy as assessed by medical history and standard physical examination You are weight stable (your body weight has not changed .6.5 lbs over the last 3 months) You do not smoke You provide written informed consent to participate in the study You are willing to stay overnight one time at the Pennington Center You have low physical activity (< 100 min of exercise per week)  You were born prematurely (<37 weeks of pregnancy) You are currently taking medication that may influence your body weight or metabolism You have heart disease, lung disease, liver disease, blood disease, kidney disease, type 1 or 2 diabetes, or any other disease that in the opinion of the doctor might make you ineligible
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diverticulitis All consecutive patients with left sided acute diverticulitis diagnosed clinically by the presence of abdominal pain leukocytosis (>11x109) fever >38°C and confirmed by imaging (CT scan, ultrasonography, water soluble contrast enema) The CT for the diagnosis included at least one of a localized thickening (≥4 mm) of the colonic wall signs of inflammation of the pericolic fat abscess extraluminal air extraluminal contrast The ultrasound included at least two of bowel wall thickening (>4 mm)  inflammatory bowel disease irritable bowel syndrome colorectal cancer diseases precluding adequate follow up
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pancreatitis Pancreatitis diagnosis of acute pancreatitis written informed consent inpatient treatment  time interval between onset of abdominal symptoms and study >96h patients unable to consent
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 16.0-50.0,  Constipation Abdominal Pain Nausea Vomiting All patients aged 16 years or older able to give informed consent undergoing their first or second elective CS  Unable to give informed consent A basic level of literacy sufficient to complete postoperative form History of constipation Regular opiate use Previous bowel surgery or bowel adhesions Lactose intolerant Diabetic Any patient unable to have spinal Anaesthesia Allergies/intolerant to bupivacaine, diamorphine, diclofenac, cocodamol, lactulose Patients receiving injury to bowel intraoperatively
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Healthy Obesity Type 2 Diabetes Mellitus General Male sex Generally healthy with specifically no known cardiovascular disease or gastric ulcers, which can affect the study parameters Stable dietary habits (no weight loss/gain > 3 kg in the last 6 months) Group 1, type 2 diabetes participants Ages 40-70 years BMI > 30 kg/m2 Non-insulin dependent type 2 diabetes Must be on sulphonylurea (SU)-derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months Well-controlled diabetes: HbA1c < 8% No diabetes related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy Group 2, obese healthy control participants  Regular smokers Participation in other studies Female sex Insulin dependent diabetic individuals Participants with diabetes related diseases (diabetic foot, diabetic polyneuropathy, diabetic retinopathy etc.) Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone) Use of anti-coagulants (not thrombocyte-aggregation inhibitors) Aberrant ECG (with signs of ischemia or cardiac failure or arrythmias) Weight gain/loss > 3 kg in the last 6 months HbA1c < 7.8 in type 2 diabetic individuals
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Serious Gram-positive Infections Patients started daptomycin therapy since January 2009 Patients completed daptomycin therapy by the end of December 2010 Patients had Gram positive infections Patients received daptomycin therapy for at least 3 days  Daptomycin therapy will be chosen by the treating physician based on clinical indication and it is expected that risks of therapy will have already been considered subjects are only to be excluded if he/she was enrolled in any antibiotics clinical trial during daptomycin treatment
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Previously fitted with an ICD or a CRT-D device for primary or secondary prevention (for at least 34 days) with a Medtronic Optivol capable Device Previous hospital admission for decompensated heart failure Left ventricular systolic dysfunction (EF <50%) Currently compensated heart failure with a functional class of III or better All patients will be on optimal medical treatment including a beta blocker, an ACEI (or ARB) and spironolactone unless contraindicated or not tolerated  Decompensated patients who have NYHA class IV or clinical signs of lung congestion at time of evaluation (these patients may be included later if/when their NYHA class improves) Patients with a high Optivol fluid index at time of evaluation (these patients may be included later when the Optivol fluid index comes down) Patients with advanced renal failure ± dialysis (Chronic Kidney Disease class 4 or 5 with an estimated GFR of <30 ml/min)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Heart Failure Left Bundle Branch Block Heart Disease years of age or older Patients willing and capable of providing informed consent, participating in all testing associated with this clinical investigation Patients undergoing a CRT implant procedure (pacemaker or defibrillator) for one of the following reasons Indicated for a new device Device upgrade Device replacement Lead revision Note: recognized indications for CRT-P and CRT-D as of October 2009 are valid for in this study. Should new indications become approved during the study conduct; those will also be applied within the criteria  Patients unwilling or incapable of signing the informed consent, or patients having previously withdrawn their consent Patients in AF that cannot be cardioverted for the study RBBB pattern Sustained, uncontrolled ventricular tachycardia Sinus rhythm < 30 bpm or >100 bpm Complete AV node block Second degree AV block Women who are pregnant or plan to become pregnant during the study (method of assessment upon physician's discretion) History of (hemorrhagic) cerebro-vascular accident or TIA
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 2 Diabetes Male or Female over 18 years of age Type 2 diabetes for at least 6 months Taking 1 or more oral hypoglycemic agents Patient attending your community pharmacy where you decided that addition of insulin glargine may be of benefit to the patient Baseline HbA1c 7.5 Signed informed consent  Have used, or currently using, Insulin History of ketoacidosis Pregnant Works night shift Renal impairment(Serum Creatinine: females ≥ 124 mmol/l, males ≥ 133 mmol/l) Clinically unstable Unwilling/unable to attend follow up visits Unlikely to adhere to study procedures (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism)